|
1
|
Konecki DS, Benedum UM, Gerdes HH and
Huttner WB: The primary structure of human chromogranin A and
pancreastatin. J Biol Chem. 262:17026–17030. 1987.PubMed/NCBI
|
|
2
|
Modlin IM, Gustafsson BI, Moss SF, Pavel
M, Tsolakis AV and Kidd M: Chromogranin A--biological function and
clinical utility in neuro endocrine tumor disease. Ann Surg Oncol.
17:2427–2443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Påhlman S, Esscher T, Bergvall P and
Odelstad L: Purification and characterization of human
neuron-specific enolase: Radioimmunoassay development. Tumour Biol.
5:127–139. 1984.PubMed/NCBI
|
|
4
|
Baudin E, Gigliotti A, Ducreux M, Ropers
J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié
P and Schlumberger M: Neuron-specific enolase and chromogranin A as
markers of neuroendocrine tumours. Br J Cancer. 78:1102–1107. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan JH, Zhang YQ, Shi SS, Chen YJ, Yuan
XH, Jiang LM, Wang SM, Ma L, He YT, Feng CY, et al: A nation-wide
retrospective epidemiological study of gastroenteropancreatic
neuroendocrine neoplasms in china. Oncotarget. 8:71699–71708.
2017.PubMed/NCBI
|
|
6
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plöckinger U, Rindi G, Arnold R, Eriksson
B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC,
et al: Guidelines for the diagnosis and treatment of neuroendocrine
gastrointestinal tumours. A consensus statement on behalf of the
European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology.
80:394–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McEntee GP, Nagorney DM, Kvols LK, Moertel
CG and Grant CS: Cytoreductive hepatic surgery for neuroendocrine
tumors. Surgery. 108:1091–1096. 1990.PubMed/NCBI
|
|
9
|
Bosman FT, Carneiro F, Hruban RH and Theis
ND: WHO classification of tumours of the digestive system. (4th).
(Lyon). International Agency for Research on Cancer.
2010.PubMed/NCBI
|
|
10
|
Chinese Pathologic Consensus Group for
Gastrointestinal and Pancreatic Neuroendocrine Neoplasm: China
Consensus Guidelines for the standards of histopathologic diagnosis
in Gastroenteropancreatic Neuroendocrine neoplasm. Chin J Pathol.
40:257–262. 2011.
|
|
11
|
Modlin IM, Lye KD and Kidd M: A 5-decade
analysis of 13,715 carcinoid tumors. Cancer. 97:934–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oberg K, Modlin IM, De Herder W, Pavel M,
Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg
J, et al: Consensus on biomarkers for neuroendocrine tumour
disease. Lancet Oncol. 16:e435–e446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen
S, St Peter J, Cherfi A and Öberg KE: Chromogranin A and
neuron-specific enolase as prognostic markers in patients with
advanced pNET treated with everolimus. J Clin Endocrinol Metab.
96:3741–3749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arnold R, Wilke A, Rinke A, Mayer C, Kann
PH, Klose KJ, Scherag A, Hahmann M, Müller HH and Barth P: Plasma
chromogranin A as marker for survival in patients with metastatic
endocrine gastroenteropancreatic tumors. Clin Gastroenterol
Hepatol. 6:820–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jianming X, Houjie L, Shukui Q and Hui LW:
Expert consensus on neuroendocrine tumors of the pancreas and
stomach in China. J Clini Oncol. 21:927–946. 2016.
|
|
16
|
Jun E, Kim SC, Song KB, Hwang DW, Lee JH,
Shin SH, Hong SM, Park KM and Lee YJ: Diagnostic value of
chromogranin A in pancreatic neuroendocrine tumors depends on tumor
size: A prospective observational study from a single institute.
Surgery. 162:120–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cimitan M, Buonadonna A, Cannizzaro R,
Canzonieri V, Borsatti E, Ruffo R and De Apollonia L: Somatostatin
receptor scintigraphy versus chromogranin A assay in the management
of patients with neuroendocrine tumors of different types: Clinical
role. Ann Oncol. 14:1135–1141. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Basturk O, Yang Z, Tang LH, Hruban RH,
Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, et
al: The high-grade (WHO G3) pancreatic neuroendocrine tumor
category is morphologically and biologically heterogenous and
includes both well differentiated and poorly differentiated
neoplasms. Am J Surg Pathol. 39:683–690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hijioka M, Ito T, Igarashi H, Fujimori N,
Lee L, Nakamura T, Jensen RT and Takayanagi R: Serum chromogranin A
is a useful marker for Japanese patients with pancreatic
neuroendocrine tumors. Cancer Sci. 105:1464–1471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z,
Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, et al: Chromogranin A
is a reliable serum diagnostic biomarker for pancreatic
neuroendocrine tumors but not for insulinomas. BMC Endocr Disord.
14:642014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang YH, Yang QC, Lin Y, Xue L, Chen MH
and Chen J: Chromogranin A as a marker for diagnosis, treatment,
and survival in patients with gastroenteropancreatic neuroendocrine
neoplasm. Medicine (Baltimore). 93:e2472014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kloppel G, Couvelard A, Perren A,
Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY,
Wiedenmann B, Papotti M, et al: ENETS Consensus guidelines for the
standards of care in neuroendocrine tumors: Towards a standardized
approach to the diagnosis of gastroenteropancreatic neuroendocrine
tumors and their prognostic stratification. Neuroendocrinology.
90:162–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lai M, Lü B, Xing X, Xu E, Ren G and Huang
Q: Secretagogin, a novel neuroendocrine marker, has a distinct
expression pattern from chromogranin A. Virchows Arch. 449:402–409.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xing X, Lai M, Gartner W, Xu E, Huang Q,
Li H and Chen G: Identification of differentially expressed
proteins in colorectal cancer by proteomics: Down-regulation of
secretagogin. Proteomics. 6:2916–2923. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D'Alessandro M, Mariani P, Lomanto D,
Carlei F, Lezoche E and Speranza V: Serum neuron-specific enolase
in diagnosis and follow-up of gastrointestinal neuroendocrine
tumors. Tumour Biol. 13:352–357. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cunningham RT, Johnston CF, Irvine GB and
Buchanan KD: Serum neurone-specific enolase levels in patients with
neuroendocrine and carcinoid tumours. Clin Chim Acta. 212:123–131.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oishi S and Sato T: Elevated serum
neuron-specific enolase in patients with malignant
pheochromocytoma. Cancer. 61:1167–1170. 1988. View Article : Google Scholar : PubMed/NCBI
|
